Stock Expert AI

Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.

The Procter & Gamble Company
PG - NYSE - $161.02 (as of ) ▼ -2.12%
-
Earnings Thu 21 Jan

Procter opens the
books on Thursday evening.

The median of 10 price targets is $1641, stock is $161, +1.5% vs the analyst consensus median.

↓ summary below
Quick Take - in 40 seconds ·
B+
Council 3/6 - Historical V1 score 51

B+ — FMP rating1. Form 4: 6 transactions1.

Quick Answer

The Procter & Gamble Company (PG) Q2 consensus: revenue $22.8B1, EPS $1.851. 7 consecutive quarters of beat1.

$1.85 EPS Estimate Last year $1.88 - -2% YoY
7 Beat Streak Expectations beaten consecutively for the last 7 quarters

Q1 FY27 EPS $2.00 vs $1.88 estimate: beat (+6.4%)1. Stock move on the next trading day: -2.8%1.

Next report

What to watch in Q2 FY27 (Jan 21, 2027)

  • EPS: consensus $1.85, against $1.88 in the same quarter a year ago (-2%).
  • Revenue: consensus $22.8B.

Watchlist

5 metrics stand out this quarter.

0%-3% Expectation / Guide

Fy27 Core Eps Guidance

P&G guides FY2027 core EPS growth of 0% to 3%, equating to $6.89 to $7.11 per share with $7 at the midpoint.

"Our bottom line outlook is broadly consistent with top-line, with core EPS growth of 0% to 3% versus 2026 core EPS of $6.89 this guidance equates to a range of $6.89 to $7.11 per share, $7 at the center of the range."

- Andre Schulten, CFO - Q4 FY26 Earnings Call - July 29, 2026
5% Investor Focus

Q1 Fy27 Eps Pressure

P&G expects Q1 FY2027 EPS to decline 5% or more versus prior year because of the cost dynamic.

Andre Schulten, CFO - Q4 FY26 Earnings Call - July 29, 2026
+2% Investor Focus

Na Sell Out Vs Sell In

In Q4 North America consumption (sell-out) grew 2% while shipments to retailers (sell-in) fell 1%, a notable disconnect.

Andre Schulten, CFO - Q4 FY26 Earnings Call - July 29, 2026
$1 billion Investor Focus

Fy27 Cost Headwind

P&G expects an after-tax cost headwind of approximately $1 billion in FY2027 from higher raw material, energy and transportation costs tied to the Middle East conflict.

Andre Schulten, CFO - Q4 FY26 Earnings Call - July 29, 2026
4.5%-5.5% Investor Focus

Fy27 Capital Spending

P&G expects FY2027 capital spending of 4.5% to 5.5% of sales.

Andre Schulten, CFO - Q4 FY26 Earnings Call - July 29, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 6 perspectives, and Munger lens point in the same direction?

Council Score 3 / 6 Bullish

6 investor frameworks. 3 bullish (Ray Dalio, Ken Griffin, Buffett), 0 bearish (none), 3 neutral (Jim Simons, Klarman, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +1.5%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 64
Klarman value - target upside +1.5%
Buffett quality - ROE score 5/5
Munger valuation - target upside +1.5%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyWeak
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
63.6 RSI 63.6 positive momentum, 50d above
MACD
+8.50 price above 50d - support positive
50d MA
$148 stock 8.5% above - short-term support
200d MA
$149 stock 8.4% above - long-term support
Volume (10d)
-10% decrease - low participation
Resistance
$164
Analyst median target - upgrade trigger if broken
Current
$161
Pre-earnings position
Support
$126
Invalidation - close below this is a technical breakdown
Pattern
Range
$126-$164 band - earnings breakout/breakdown trigger

Past Performance

4 quarters shown.

BEAT
Q2 FY26
$1.88 vs $1.86 est · Next-day price move: +0.1%
BEAT
Q3 FY26
$1.59 vs $1.56 est · Next-day price move: +0.1%
BEAT
Q4 FY26
$1.43 vs $1.41 est · Next-day price move: -1.5%
BEAT
Q1 FY27
$2.00 vs $1.88 est · Next-day price move: -2.8%

Q1 FY27 (October 22, 2026) EPS $2.00 vs $1.88 estimate: beat (+6.4%)1.

Three scenarios: what could happen?

EPS < $1.79 (no guidance)

"Taken together, our guidance range is for organic sales growth of 1% to 3% versus prior year"

- Andre Schulten, CFO - Q4 FY26 Earnings Call - July 29, 2026
Backlog concentration

No RPO/backlog concentration disclosed in Q4 earnings call.

Insider trading signal

Form 4 Q1 FY27: 6 transactions, net -$2.17M1.

Executive Action Amount Date
Schulten Andre Chief Financial Officer Sale -$568.9K 2026-10-06
Gama Paul CEO- Health Care Sale -$323.4K 2026-10-06
Whaley Susan Street Chief Legal Officer & Secy Sale -$344.3K 2026-10-06
Aguilar Moses Victor Javier Chf Rsch, Dev & Innov Officer Sale -$439.0K 2026-08-27
Janzaruk Matthew W. SVP - Chief Accounting Officer Sale -$52.1K 2026-08-24
Aguilar Moses Victor Javier Chf Rsch, Dev & Innov Officer Sale -$439.0K 2026-08-24

6 transactions · 6 sales / 0 purchases = net negative flow. Not large in absolute terms against a $373.2B market cap.

CapEx shock

Q4 CapEx $1.4B1. Q4 op margin 25.5%1 - this level in Q2 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q2 EPS > $1.85 + CapEx discipline
Threshold: EPS > $1.851.
Target: Break above median target $1641; high target $1901 upper bound.
Scenario B - In-Line
EPS approx $1.85 + CapEx < $1.4B
Threshold: EPS approx $1.851, Q2 CapEx < $1.4B1.
Target: Consolidation in the band between current $1611 and median $1641.
Scenario C - Miss
EPS < $1.79 or CapEx >= $1.4B
Threshold: EPS < $1.791.
Current price $161 — above SMA200 $1491.

Market Outlook

What do analysts say? 10 price targets · 27 ratings

Wall Street Consensus
$164
12-month median target price (+1.5% gap to the analyst consensus median)
15
BUY
12
HOLD
0
SELL
Risk Management
$126
Invalidation level - critical support threshold
$148 - 50-day MA (above, +8.5%)
$149 - 200-day MA (above, +8.4%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - PG Q2 FY27
B+

You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Thursday evening. The framework is ready on this page: Q2 EPS threshold $1.851, CapEx threshold "below $1.4B". Two anchors, three scenarios.

Comparison Stock Expert AI is free today — no credit card.

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jan 21, 2027EARNINGSQ2 FY27 results (after market close) + earnings call
Jan 22, 2027PRICEFirst trading day after earnings - 200dMA test + IV crush
Feb 9, 2027 – Feb 14, 2027FILING10-Q due within 40–45 days of quarter end (by Feb 9, 2027 – Feb 14, 2027); the exact deadline depends on filer status
~Apr 23, 2027EARNINGSQ3 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the PG Q2 FY27 earnings preview cover?

This The Procter & Gamble Company (PG) Q2 FY27 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in PG Q2 FY27 earnings?

The Procter & Gamble Company (PG): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

The Procter & Gamble Company (PG): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

The Procter & Gamble Company (PG): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded